Comparison of cases classified according to the WHO/EORTC classification
. | LBCLLT . | LBCLO . | FCLDT . |
|---|---|---|---|
| Sex, M:F | 0.6:1 | 0.3:1 | 1.3:1 |
| 5-y survival, % | |||
| Disease-specific | 61.7 | 50.0 | 86.7 |
| Overall | 52.9 | 50.0 | 77.5 |
| 10-y survival, % | |||
| Disease-specific | 0 | 50.0 | 86.7 |
| Overall | 0 | 50.0 | 66.5 |
| Disease-specific survival according to diagnostic category, P | — | .04* | — |
| Overall survival according to diagnostic category, P | — | .03† | — |
| Median age, y | 79 | 70 | 66.5 |
| Disease-specific survival according to age older than 70 y versus age 70 or younger, P | .8 | NA | .03 |
| Solitary/multiple lesions | 20/20 | 7/2 | 12/32 |
| Disease-specific survival according to number of lesions, P | .5 | NA | .6 |
| Site | |||
| Leg/total (%) | 32/40 (80) | 5/9 (55.6) | 5/44 (11.4) |
| Disease-specific survival according to anatomic site (leg vs not the leg), P | .6 | NA | .02 |
| Bcl-2 | |||
| +/total (%) | 40/40 (100) | 0/9 (0) | 10/44 (22.7) |
| Disease-specific survival according to Bcl-2 expression, P | — | — | P>.999 |
| FOX-P1 | |||
| +/total (%) | 23/29 (72.4) | 3/6 (50) | 4/40 (10) |
| Disease-specific survival according to FOX-P1 expression, P | .5 | NA | .6 |
| MUM-1 | |||
| +/total (%) | 22/29 (75.9) | 4/6 (66.7) | 3/43 (7) |
| Disease-specific survival according to MUM-1 expression, P | .9 | NA | .07 |
| Bcl-6/CD10 expression | |||
| Bcl-6, +/total (%) | 30/40 (75) | 7/7 (100) | 41/44 (93.2) |
| CD10, +/total (%) | 2/33 (6.1) | 1/7 (14.3) | 7/39 (17.9) |
| Bcl-6−/CD10− phenotype, +/total (%) | 10/40 (25) | 0/7 (0) | 3/44 (6.8) |
| Disease-specific survival according to CD10/Bcl-6 expression, P | .5 | NA | .2 |
. | LBCLLT . | LBCLO . | FCLDT . |
|---|---|---|---|
| Sex, M:F | 0.6:1 | 0.3:1 | 1.3:1 |
| 5-y survival, % | |||
| Disease-specific | 61.7 | 50.0 | 86.7 |
| Overall | 52.9 | 50.0 | 77.5 |
| 10-y survival, % | |||
| Disease-specific | 0 | 50.0 | 86.7 |
| Overall | 0 | 50.0 | 66.5 |
| Disease-specific survival according to diagnostic category, P | — | .04* | — |
| Overall survival according to diagnostic category, P | — | .03† | — |
| Median age, y | 79 | 70 | 66.5 |
| Disease-specific survival according to age older than 70 y versus age 70 or younger, P | .8 | NA | .03 |
| Solitary/multiple lesions | 20/20 | 7/2 | 12/32 |
| Disease-specific survival according to number of lesions, P | .5 | NA | .6 |
| Site | |||
| Leg/total (%) | 32/40 (80) | 5/9 (55.6) | 5/44 (11.4) |
| Disease-specific survival according to anatomic site (leg vs not the leg), P | .6 | NA | .02 |
| Bcl-2 | |||
| +/total (%) | 40/40 (100) | 0/9 (0) | 10/44 (22.7) |
| Disease-specific survival according to Bcl-2 expression, P | — | — | P>.999 |
| FOX-P1 | |||
| +/total (%) | 23/29 (72.4) | 3/6 (50) | 4/40 (10) |
| Disease-specific survival according to FOX-P1 expression, P | .5 | NA | .6 |
| MUM-1 | |||
| +/total (%) | 22/29 (75.9) | 4/6 (66.7) | 3/43 (7) |
| Disease-specific survival according to MUM-1 expression, P | .9 | NA | .07 |
| Bcl-6/CD10 expression | |||
| Bcl-6, +/total (%) | 30/40 (75) | 7/7 (100) | 41/44 (93.2) |
| CD10, +/total (%) | 2/33 (6.1) | 1/7 (14.3) | 7/39 (17.9) |
| Bcl-6−/CD10− phenotype, +/total (%) | 10/40 (25) | 0/7 (0) | 3/44 (6.8) |
| Disease-specific survival according to CD10/Bcl-6 expression, P | .5 | NA | .2 |